genomma lab internacional sab de cv - GNMLF

GNMLF

Close Chg Chg %
1.04 -0.04 -3.84%

Open Market

1.00

-0.04 (3.84%)

Volume: 100.00

Last Updated:

Feb 2, 2026, 9:30 AM EDT

Company Overview: genomma lab internacional sab de cv - GNMLF

GNMLF Key Data

Open

$1.00

Day Range

1.00 - 1.00

52 Week Range

0.93 - 1.27

Market Cap

$1.06B

Shares Outstanding

1.00B

Public Float

671.33M

Beta

0.55

Rev. Per Employee

N/A

P/E Ratio

12.34

EPS

$0.09

Yield

393.43%

Dividend

$0.01

EX-DIVIDEND DATE

Mar 30, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

1.50K

 

GNMLF Performance

No Data Available

GNMLF Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About genomma lab internacional sab de cv - GNMLF

Genomma Lab Internacional SAB de CV engages in the development, manufacturing and marketing of pharmaceutical, beauty and personal care products. The company was founded by Rodrigo Alonso Herrera Aspra on October 30, 1996 and is headquartered in Mexico City, Mexico.

GNMLF At a Glance

Genomma Lab Internacional SAB de CV
Avendia Antonio Dovalí Jaime, 70
Mexico City, Ciudad de Mexico 01210
Phone 52-55-5081-0000 Revenue 913.58M
Industry Pharmaceuticals: Major Net Income 83.72M
Sector Health Technology Employees 1,465
Fiscal Year-end 12 / 2026
View SEC Filings

GNMLF Valuation

P/E Current 12.34
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 11.583
Price to Sales Ratio 1.064
Price to Book Ratio 1.573
Price to Cash Flow Ratio 13.45
Enterprise Value to EBITDA 5.78
Enterprise Value to Sales 1.354
Total Debt to Enterprise Value 0.343

GNMLF Efficiency

Revenue/Employee 623,606.883
Income Per Employee 57,144.326
Receivables Turnover 2.292
Total Asset Turnover 0.751

GNMLF Liquidity

Current Ratio 1.775
Quick Ratio 1.438
Cash Ratio 0.395

GNMLF Profitability

Gross Margin 62.836
Operating Margin 21.264
Pretax Margin 13.874
Net Margin 9.164
Return on Assets 6.883
Return on Equity 14.668
Return on Total Capital 8.032
Return on Invested Capital 10.122

GNMLF Capital Structure

Total Debt to Total Equity 68.644
Total Debt to Total Capital 40.704
Total Debt to Total Assets 32.001
Long-Term Debt to Equity 43.161
Long-Term Debt to Total Capital 25.593
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Genomma Lab Internacional Sab De Cv - GNMLF

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
835.84M 928.21M 1.02B 913.58M
Sales Growth
+9.51% +11.05% +9.36% -10.00%
Cost of Goods Sold (COGS) incl D&A
330.78M 359.84M 364.20M 339.53M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
11.29M 12.81M 19.62M 19.75M
Depreciation
- - - -
-
Amortization of Intangibles
- - - -
-
COGS Growth
+13.30% +8.79% +1.21% -6.77%
Gross Income
505.06M 568.36M 650.90M 574.06M
Gross Income Growth
+7.16% +12.53% +14.52% -11.80%
Gross Profit Margin
+60.43% +61.23% +64.12% +62.84%
2022 2023 2024 2025 5-year trend
SG&A Expense
344.00M 385.45M 439.44M 379.79M
Research & Development
- - - -
-
Other SG&A
344.00M 385.45M 439.44M 379.79M
SGA Growth
+6.23% +12.05% +14.01% -13.57%
Other Operating Expense
- (3.07M) (402.29K) (1.60M)
Unusual Expense
- - 872.92K 3.89K
-
EBIT after Unusual Expense
163.27M 183.31M 213.06M 194.27M
Non Operating Income/Expense
(26.13M) (36.25M) (6.90M) (12.94M)
Non-Operating Interest Income
5.87M 8.85M 5.79M 5.87M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
26.12M 46.78M 48.43M 54.58M
Interest Expense Growth
+19.26% +79.09% +3.54% +12.69%
Gross Interest Expense
26.12M 46.78M 48.43M 54.58M
Interest Capitalized
- - - -
-
Pretax Income
111.02M 100.29M 157.72M 126.75M
Pretax Income Growth
-2.58% -9.67% +57.27% -19.64%
Pretax Margin
+13.28% +10.80% +15.54% +13.87%
Income Tax
43.11M 35.83M 43.64M 43.03M
Income Tax - Current - Domestic
- 54.60M 41.41M 52.12M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- (11.48M) (5.58M) (8.48M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
69.03M 61.15M 114.08M 83.72M
Minority Interest Expense
- - - -
-
Net Income
69.03M 61.15M 114.08M 83.72M
Net Income Growth
+7.10% -11.42% +86.55% -26.62%
Net Margin Growth
+8.26% +6.59% +11.24% +9.16%
Extraordinaries & Discontinued Operations
- - - (32.62M)
-
Discontinued Operations
- - - (32.62M)
-
Net Income After Extraordinaries
69.03M 61.15M 81.46M 83.72M
Preferred Dividends
- - - -
-
Net Income Available to Common
69.03M 61.15M 81.46M 83.72M
EPS (Basic)
0.0695 0.0639 0.0833 0.0859
EPS (Basic) Growth
+8.59% -8.06% +30.36% +3.12%
Basic Shares Outstanding
- 993.23M 957.34M 978.43M
EPS (Diluted)
0.0695 0.0639 0.0833 0.0859
EPS (Diluted) Growth
+8.59% -8.06% +30.36% +3.12%
Diluted Shares Outstanding
- 993.23M 957.34M 978.43M
EBITDA
175.43M 196.13M 232.68M 214.01M
EBITDA Growth
+12.39% +11.80% +18.63% -8.02%
EBITDA Margin
+20.99% +21.13% +22.92% +23.43%

Genomma Lab Internacional Sab De Cv in the News